Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.44 |
| ▸ | NPY1R | P25929 | 6/20 | 0.44 |
| ▸ | NPY2R | P49146 | 4/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | OTC | P00480 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320943 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL29532212 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30340047 | 0.97 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL29939543 | 0.95 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30898573 | 0.94 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30716491 | 0.94 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30148421 | 0.92 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30945402 | 0.92 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL29799968 | 0.92 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30456493 | 0.92 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | claimed |
| CN-119326868-B | Ginseng antler refined component and preparation method and application thereof | 长春中医药大学 | 2025-04-11 | — | — | CN | claimed |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | AMGEN INC. (US) | 2025-03-25 | — | — | US | claimed |
| CN-119326868-A | Ginseng antler refined component and preparation method and application thereof | 长春中医药大学 | 2025-01-21 | — | — | CN | claimed |
| US-20250011340-A1 | BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF | IMMUNOGEN, INC. | 2025-01-09 | — | — | US | claimed |
| CN-113769108-B | Conjugates of cysteine engineered antibodies | 伊缪诺金公司 | 2024-11-08 | — | — | CN | claimed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | claimed |
| EP-4412671-A1 | ANTI-THROMBOGENIC COATING | Medtronic, Inc. (US) | 2024-08-14 | — | — | EP | claimed |
| EP-4374850-A2 | METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES | ImmunoGen, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | claimed |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | claimed |
| WO-2023059649-A1 | ANTI-THROMBOGENIC COATING | MEDTRONIC, INC. (US) | 2023-04-13 | — | — | WO | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | claimed |
| US-20220372152-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2022-11-24 | — | — | US | claimed |
| WO-2022173981-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. (US) | 2022-08-18 | — | — | WO | claimed |
| CN-106604927-B | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2022-08-09 | — | — | CN | claimed |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2022-05-17 | — | — | US | claimed |
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | NPY4R 542/4885NPY1R 294/4885NPY2R 565/4885 |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | ARGLU1, ARG1, FCGRT | NPY4R 1403/4885NPY1R 1084/4885NPY2R 1670/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | NPY4R 1324/4885NPY1R 625/4885NPY2R 784/4885 |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | ARGLU1, ARG1, FCGRT | NPY4R 1403/4885NPY1R 1084/4885NPY2R 1670/4885 |
| US-20250011340-A1 | BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF | GABRA6, GABRA2, GABRA1 | NPY4R 1186/4885NPY1R 975/4885NPY2R 1467/4885 |
| US-20220372152-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | NPY4R 1743/4885NPY1R 1558/4885NPY2R 1580/4885 |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | NPY4R 1743/4885NPY1R 1558/4885NPY2R 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.